Abstract
Chimeric antigen receptor T-cell therapy is a form of adoptive immunotherapy that is promising for the treatment of hematologic malignancies. Solve it!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhang H, Zhao P, Huang H. Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol. 2020;9:34. https://doi.org/10.1186/s40164-020-00190-2.
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9.
Lana MG, Strauss BE. Production of lentivirus for the establishment of CAR-T cells. Methods Mol Biol. 2020;2086:61–7.
Holmes B. CAR T-cell therapy indications grow significantly in 2021. Targeted Ther Oncol. 2021;10(8):10. https://www.targetedonc.com/view/car-t-cell-therapy-indications-grow-significantly-in-2021
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.
Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes. Clin Lymphoma Myeloma Leuk. 2021;21(4):e334–7.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.
Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81. https://doi.org/10.1186/s13287-020-02128-1.
Novartis Pharmaceuticals Corp. KYMRIAH® prescribing information. East Hanover: Novartis Pharmaceuticals Corp.; 2020.
Kite Pharma, Inc. YESCARTA® prescribing information. Santa Monica: Kite Pharma, Inc.; 2022.
Kite Pharma, Inc. TECARTUS® prescribing information. Santa Monica: Kite Pharma, Inc.; 2021.
Celgene Corp. ABECMA® prescribing information. Summit: Celgene Corp.; 2021.
Juno Therapeutics, Inc. BREYANZI® prescribing information. Bothell: Juno Therapeutics, Inc.; 2021.
Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133–41.
Korell F, Laier S, Sauer S, Veelken K, Hennemann H, Schubert M-L, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL. Cell. 2020;9(5):1225.
Further Reading
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9.
Kuldanek S, Pasko B, DomBourian M, Annen K. Cellular therapy in pediatric hematologic malignancies. Clin Lab Med. 2021;41(1):121–32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). “CAR T”-esian Thinking. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_95
Download citation
DOI: https://doi.org/10.1007/978-3-031-14638-1_95
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14637-4
Online ISBN: 978-3-031-14638-1
eBook Packages: MedicineMedicine (R0)